<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1924">
  <stage>Registered</stage>
  <submitdate>15/04/2008</submitdate>
  <approvaldate>15/04/2008</approvaldate>
  <nctid>NCT00659893</nctid>
  <trial_identification>
    <studytitle>Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2</studytitle>
    <scientifictitle>A Multi-center, Open Label, Dose-area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-022</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005 Topical gel

Experimental: 1 - Cohort 1 One 25 cm2 treatment area; on one arm

Experimental: 2 - Cohort 2 One 50cm2 contiguous treatment area; on one arm

Experimental: 3 - Cohort 3 Two 25cm2 treatment areas; one on each arm

Experimental: 4 - Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm

Experimental: 5 - Cohort 5 One 75cm2 contiguous treatment area; on one arm

Experimental: 6 - Cohort 6 Two 50cm2 contiguous treatment area; one on each arm

Experimental: 7 - Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm

Experimental: 8 - Cohort 8 One 100cm2 contiguous treatment area; on one arm


Treatment: drugs: PEP005 Topical gel
0.05%, two day dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability (incidence of AEs, SAEs and skin responses)</outcome>
      <timepoint>Screening to End of Study (Day 57)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must be male and at least 18 years of age.

          -  A 100 cm2 contiguous treatment area on each of the right and left extensor (dorsal
             aspect) forearms, each containing a minimum of 5 AK lesions.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision,
             curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing):
             within 2 weeks and within 2 cm of the selected treatment area(s).

          -  Treatment with immunomodulators, or interferon/ interferon inducers or systemic
             medications that suppress the immune system: within 4 weeks.

          -  Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks
             and within 2 cm of the selected treatment area(s).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>64</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>St George Dematology and Skin and Cancer Centre - Kogarah, Sydney</hospital>
    <hospital>South East Dermatology, Belmont Specialist Centre - Carina Heights, Brisbane</hospital>
    <hospital>Skin and Cancer Foundation - Carlton, Melbourne</hospital>
    <hospital>St John of God Dermatology - Subiaco, Perth</hospital>
    <hospital>Burswood Dermatology - Victoria Park, Perth</hospital>
    <postcode>2217 - Kogarah, Sydney</postcode>
    <postcode>4152 - Carina Heights, Brisbane</postcode>
    <postcode>3053 - Carlton, Melbourne</postcode>
    <postcode>6008 - Subiaco, Perth</postcode>
    <postcode>6100 - Victoria Park, Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25
      cm2 treatment areas, as compared to individual 25 cm2 treatment areas.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00659893</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>George Schmieder, DO</name>
      <address>Park Avenue Dermatology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>